The successful investor's hedge fund is always hunting for new stock picks, so tracking its new buys could be a great source of new stock ideas.
Data from a small-cap biotech stock that's working with Celgene on a new approach to cancer treatment is expected in 2018.
Berkshire Hathaway's portfolio doesn't change very often, but when it does, investors ought to know about it, especially if they own stocks Warren Buffett is selling.
The provider of specialized health services grew its year-over-year revenue thanks to acquisitions, but its profits sank.
The company's story is finally untied from its failed relationship with Johnson & Johnson.
A flurry of news has investors clamoring to add Nektar Therapeutics to their portfolios.
Using a market sell-off to buy shares in fast-growing technology stocks could pay off nicely for investors.
The world's best stock picker just released his latest buys, and these three companies were his biggest buys last quarter.
A strong economy and low unemployment make it a good time to consider adding bank stocks to your portfolio.
Worry about whether drug pricing will return to the forefront in Washington, D.C. is increasing following Donald Trump's nomination of a drug-industry insider as his next Department of Health and Human Services secretary.
The global pharmaceutical giant has signed a deal that could be worth more than $1.5 billion to this clinical-stage cancer drug developer.
The company's making inroads with its first commercial-stage drug, but expenses could present big headwinds.
Encouraging results for one of its drugs in solid tumor cancers are sparking interest in the clinical-stage company.
Healthcare stocks are some of the most intriguing long-term stocks to buy. Picking up these stars now could end up being very profit-friendly.
Rising crude oil prices and falling offshore development costs could help this struggling industry recover.
A big-money investment in marijuana hints at the money-making potential of this emerging industry.
This company took important steps forward last quarter to continue growing.
The life sciences industry is growing quickly and that may lead to market-beating returns for this company.
This fast-growing company is already profiting from the growing adoption of Internet of Things.
A confusing quarter and pipeline uncertainty have investors scratching their heads over what to do with this biotech stock.